The Lovelace Heart Hospital is celebrating the new addition of their 1,000th heart device. Called the Watchman, the device ...

For patients with atrial fibrillation who need protection from stroke and other complications after ablation, left atrial ...

Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

Abbott (NYSE:ABT) announced new data supporting its Amplatzer Amulet left atrial appendage (LAA) occluder system.

Boston Scientific Corporation BSX recently announced favorable three-year primary endpoint data from the OPTION global ...

Marlborough, Massachusetts Tuesday, November 19, 2024, 17:00 Hrs [IST] ...

The trial compared the stroke prevention device for left atrial appendage closure to blood thinners in people who underwent ...

Left atrial appendage closure is an alternative strategy for stroke prophylaxis, Wazni and colleagues noted. "The safety and ...

Boston Scientific (BSX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Larry ...

Boston Scientific announced positive three-year primary endpoint results from a clinical trial of its Watchman FLX device.

5.0%). The OPTION trial included 1,600 patients. In the trial, approximately 60% of device patients had their WATCHMAN FLX ...

The trial met its primary safety and efficacy endpoints, demonstrating the device's superiority to oral anticoagulants.